XBiotech announces the first patient registered at the National Cancer Institute (INCA) … | New

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) — XBiotech (NASDAQ: XBIT) today announced the enrollment of the first patient in a multicenter randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of cancer colorectal. The highly anticipated clinical study of XBiotech’s cancer treatment candidate is funded by the National Cancer Institute (INCA). The study is led by renowned oncologists, Dr. François Ghiringhelli and Dr. Come Lepage, professor of medical oncology and director of the INSERM research team at the Georges-François Leclerc Cancer Center, and professor in the Department of Gastro- enterology and digestive oncology at the CHU. Dijon, Dijon, France, respectively.

Researchers combine XBiotech’s Natrunix with trifluridine/tipiracil as a new treatment candidate for metastatic colorectal cancer. Subjects receiving the experimental treatment failed prior treatment with oxaliplatin, irinotecan and fluoropyrimidine. Subjects are randomized to receive Natrunix plus trifluridine/tipiracil chemotherapy or placebo plus chemotherapy. The study is designed to progress seamlessly through Phase III development based on the achievement of certain efficacy milestones in Phases I/II.

Natrunix is ​​a therapeutic monoclonal antibody discovered, manufactured and under clinical development by XBiotech. The antibody blocks the activity of the substance produced by tumors and inflammatory cells that stimulates the formation of new blood vessels and breaks down connective tissue at the tumor site, allowing tumors to grow and spread. The same substance also activates blood vessels, making them sticky to improve the migration of circulating tumor cells to new sites of metastasis. Natrunix powerfully blocks the action of the substance, known as IL-1, which is also produced in response to chemotherapy.

Colorectal cancer is one of the most common forms of cancer in Europe and the United States, with the American Cancer Society estimating over 151,000 new cases and over 52,000 deaths per year in the United States alone.

About True Human™ Therapeutic Antibodies

XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs in multiple disease areas, XBiotech’s True Human Antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech

XBiotech is a fully integrated, global bioscience company dedicated to the discovery, development and commercialization of antibody therapeutics based on its proprietary True Human™ technology. XBiotech is currently developing a strong portfolio of antibody therapies to redefine the standards of care in oncology, inflammatory and infectious diseases. Based in Austin, Texas, XBiotech has also developed innovative biotech manufacturing technology designed to quickly and cost-effectively produce its real human antibodies. For more information, visit www.xbiotech.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding management’s beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “would”, “could”, “expect”, “anticipate”, ” contemplates”, “anticipates”, “believes”, “estimates”, “predicts”, “plans”, “intends” or “continues” or the negative form of these terms or other comparable terms, although all forward-looking statements do not contain such identifying words.Forward-looking statements are subject to risks and uncertainties inherent in predicting future results and conditions that could cause actual results to differ materially from those projected in such forward-looking statements. These risks and uncertainties are subject to the information set forth in the “Risk Factors” section of certain of our filings with the SEC. Forward-looking statements are not guarantees of future performance, and our actual results of operations, condition financial situation and our liquidity, as well as the development of the sector in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements we make in this press release speak only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.


Wenyi Wei

[email protected]

Such. 737-207-4600

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.